“NASH is rising at a staggering rate, and successful treatment of non-human primates with our drug candidate, DT-109, brings ...

The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was ...

Akero’s treatment for NASH falls short in cirrhosis study. By Adam Feuerstein Oct. 10, 2023. ... The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, ...

Akero treatment for NASH reduces liver scarring, achieves goals of mid-stage study. By Adam Feuerstein Sept. 13, 2022. Reprints. Adobe.

The FDA has granted accelerated approval to Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced ...

NASH is a serious liver condition that does not have an FDA-approved treatment. Madrigal Pharmaceuticals' stock jumped more than 200% on Monday after the biotech released positive results for its ...

Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH. By Frank Vinluan on September 06, 2023 1:23 pm. Share. Share Options.

Intercept Pharmaceuticals, Inc. ICPT announced that the FDA has accepted the company’s new drug application (NDA) for obeticholic acid (OCA) that seeks accelerated approval for the treatment of ...

Revolutionary Breakthrough in NASH Management: New Treatment Offers Unprecedented Hope for Liver Fibrosis PatientsPune, March 17, 2024 (GLOBE NEWSWIRE) -- The recent FDA approval of Resmetirom ...

Treatment with anti-MOSPD2 antibodies was shown to decrease inflammation and fibrosis in a NASH model and significantly reduce disease activity in a colitis model.